Current Clinical Trials
Breast center of Excellence for research
To inquire about the Breast Cancer Center of Excellence’s ongoing clinical trials, please reach the clinical research team on 01-350000 Ext: 5110, 7804 or 7803
For international clinical trials on Breast Cancer, please check the following link: https://clinicaltrials.gov/
Ongoing breast cancer clinical research projects :
Breast
- CLEE011F2301 trial (MONALEESA-3): A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment
- CLEE011E2301 (MONALEESA-7): A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non- steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
- A Multicenter Open-Label,Single Arm Study Of Pertuzumab In Combination With Tstuzumab And A Taxane In First Line Treatment Of Patients Advanced ( Metastatic Or Locally Advanced) Breast Cancer
- A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/ HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study
- Triple Negative Breast Cancer Prospective Registry in Eastern Europe, Middle East, and Africa Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer (POSITIVE)
- CBYL719C2401 – PIK3CA Registry A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer.
QUICK LINKS
